8-K: Codexis Reports Q2 2026 Results, Completes $25M Capital Raise

Codexis announced its second quarter 2026 financial results, reporting $14.9 million in revenue and reiterating full-year guidance, alongside a successful $25 million equity capital raise.

Summary

• Codexis reported $14.9 million in revenue for the second quarter of 2026, a slight decrease from $15.3 million in Q2 2025, primarily due to lower R&D revenue.
• Product gross margin improved to 73% from 72% year-over-year, driven by a shift towards higher-margin products.
• Research and Development expenses decreased to $11.7 million from $13.8 million in Q2 2025.
• Selling, General & Administrative expenses also decreased to $10.9 million from $12.3 million in Q2 2025.
• The net loss for Q2 2026 was $12.0 million ($0.13 per share), an improvement from a net loss of $13.3 million ($0.16 per share) in Q2 2025.
• The company successfully completed an equity financing in July, raising approximately $25 million in net proceeds, bringing proforma cash to approximately $80 million.
• Full-year 2026 financial guidance was reiterated, with total revenues expected between $72 million and $76 million, and gross margin in the high 60% range.
• Codexis expects its current cash position to fund operations through the end of 2028.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with a successful capital raise and progress in technology development, though revenue saw a slight dip.

Positives

• Successful completion of an equity financing in July, raising approximately $25 million in net proceeds, significantly strengthening the balance sheet and resulting in proforma cash of approximately $80 million.
• Product gross margin increased to 73% in Q2 2026 from 72% in Q2 2025, attributed to a favorable shift in sales mix towards more profitable products.
• Net loss improved to $12.0 million ($0.13 per share) in Q2 2026 from $13.3 million ($0.16 per share) in Q2 2025.
• Reiteration of full-year 2026 financial guidance, indicating management's confidence in achieving revenue targets of $72 million to $76 million.
• Projected cash runway sufficient to fund operations through the end of 2028, including expenses for GMP facility build-out.
• Demonstrated progress in the ECO Synthesis Manufacturing Platform, with new data presented at TIDES US showing enzyme-driven stereoisomer control of siRNA and initiation of enzymatic RNA synthesis from a single nucleotide.

Negatives

• Total revenues for Q2 2026 were $14.9 million, a slight decrease compared to $15.3 million in Q2 2025, primarily due to lower research and development revenue.
• Research and Development expenses, while decreased year-over-year, remain a significant operational cost at $11.7 million for the quarter.
• Selling, General & Administrative expenses also remain substantial at $10.9 million for the quarter.

Risks

• Dependence on licensees and collaborators, with the risk that development programs may be terminated.
• Reliance on a limited number of products and customers, and potential adverse effects if customer products are not well-received.
• Challenges in successfully developing and commercializing new technology and products, including the ECO Synthesis manufacturing platform.
• Competition from companies with greater resources and experience that could develop superior technologies.
• Uncertainty in advancing partnerships with drug innovators and establishing strategic partnerships with CDMOs.
• Risks associated with the timing, cost, and successful completion of the GMP facility retrofit construction.
• Potential regulatory hurdles for enzymatically synthesized oligonucleotides and a longer or more uncertain regulatory pathway.
• Potential need for additional capital in the future, with no guarantee of availability on acceptable terms.

Future Outlook

Codexis reiterates its full-year 2026 financial guidance, expecting total revenues between $72 million and $76 million and a gross margin in the high 60% range. The company anticipates its current cash reserves will be sufficient to fund operations through the end of 2028, including expenses for the GMP production facility build-out.

Management Comments

• "I am pleased with the strong financial results reported today for the second quarter of 2026," stated Alison Moore, PhD, President and Chief Executive Officer of Codexis.
• "We have made significant progress in the first half of 2026 in industrializing our ECO Synthesis Manufacturing Platform, and look forward to continued demonstration of the value of our technology to our customers in the second half."

Industry Context

StockSavvy.ai notes that Codexis operates in the specialized field of enzymatic solutions for therapeutic manufacturing, a growing area driven by the demand for more efficient and sustainable production methods for complex molecules like siRNA. The company's focus on its ECO Synthesis Manufacturing Platform positions it to capitalize on advancements in RNA therapeutics.

Comparison to Industry Standards

• The filing highlights the ECO Synthesis manufacturing platform's improved sustainability metrics compared to Solid-Phase Oligonucleotide Synthesis, the current industry standard for siRNA manufacturing.
• Codexis's technology aims to provide enzyme-driven stereoisomer control of siRNA, potentially enhancing potency and product quality, which is a key area of development in the RNA therapeutics field.

Stakeholder Impact

• Shareholders benefit from the successful capital raise, strengthening the company's financial position and extending its cash runway.
• Customers in the siRNA field may benefit from advancements in manufacturing technology, potentially leading to improved potency and quality of therapeutics.
• CDMO partners may see increased opportunities for collaboration and strategic partnerships.

Next Steps

• Submit application for a building permit for the ECO GMP Manufacturing Center in the second half of 2026.
• Commence retrofit construction of the ECO GMP Manufacturing Center during the second half of 2026.
• Expand relationships with CDMO partners with a goal of commencing an additional strategic partnership by the end of 2026.
• Advance partnerships with drug innovators toward clinical stage manufacturing agreements.
• Continue engagement with the FDA Emerging Technologies team regarding ECO Synthesis-derived siRNA product quality, stereoisomer control, and product comparability.
• Anticipate a meeting with the FDA in the fourth quarter of 2026.

Key Dates

Recommendation

The company has demonstrated technological progress and successfully raised capital, which are positive indicators. However, revenue saw a slight year-over-year decrease, and the company continues to operate at a net loss. The reiteration of guidance and extended cash runway are supportive, but the path to profitability and significant revenue growth remains to be fully demonstrated. Therefore, a 'hold' recommendation is appropriate pending further evidence of sustained revenue growth and commercial traction.

Keywords

enzymatic solutions, therapeutics manufacturing, siRNA, RNAi, GMP manufacturing, CodeEvolver, ECO Synthesis, biotechnology